All Outputs (588)

CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden (2025)
Journal Article
Calthorpe, R. J., Saumtally, H. A., Howells, L. M., Goodchild, N. J., Evans, B. C., Elliott, Z., Hayee, B. H., Carr, S. B., Elston, C. M., Horsley, A. A., Peckham, D. G., Barr, H. L., Major, G. A., Stewart, I. D., Thomas, K. S., & Smyth, A. R. (2025). CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden. Mayo Clinic Proceedings: Digital Health, 3(2), Article 100203. https://doi.org/10.1016/j.mcpdig.2025.100203

Objective
To develop a cystic fibrosis (CF)–specific patient-reported outcome measure (PROM) to measure the daily burden of gastrointestinal symptoms for people with cystic fibrosis (pwCF) aged 12 years and older and address the lack of validated ou... Read More about CF Tummy Tracker: A Cystic Fibrosis–Specific Patient-Reported Outcome Measure for Daily Gastrointestinal Symptom Burden.

Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function (2025)
Journal Article
Dellschaft, N., Murray, K., Ren, Y., Marciani, L., Gowland, P., Spiller, R., & Hoad, C. (2025). Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function. Neurogastroenterology and Motility, 37(4), Article e14999. https://doi.org/10.1111/nmo.14999

Background
The human colon receives 2 L of fluid daily. Small changes in the efficacy of absorption can lead to altered stool consistency with diarrhea or constipation. Drugs and formulations can also alter colonic water, which can be assessed using... Read More about Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function.

Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis (2024)
Journal Article
Salahi-Niri, A., Nabavi-Rad, A., Monaghan, T. M., Rokkas, T., Doulberis, M., Sadeghi, A., Zali, M. R., Yamaoka, Y., Tacconelli, E., & Yadegar, A. (in press). Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis. BMC Medicine, 22(1), Article 598. https://doi.org/10.1186/s12916-024-03816-y

Background
Helicobacter pylori infection causes gastritis, peptic ulcers, and gastric cancer. The infection is typically acquired in childhood and persists throughout life. The major impediment to successful therapy is antibiotic resistance. This sy... Read More about Global prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis.

Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation (2024)
Journal Article
Aliyu, A., Dellschaft, N., Hoad, C., Williams, H., Gaudoin, E., Sulaiman, S., Crooks, C., Gowland, P., Alexia, A., Lange, R., Bois de Fer, B., Corsetti, M., Marciani, L., & Spiller, R. (2025). Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation. Clinical Pharmacology and Therapeutics, 177(5), 1284-1291. https://doi.org/10.1002/cpt.3532

Bisacodyl is a widely used laxative that stimulates both motility and secretion. Our aim was to exploit the unique capabilities of MRI to define bisacodyl's mode of action. Two placebo-controlled cross-over trials were performed, one using a single d... Read More about Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation.

Novel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging (2024)
Journal Article
Akbar, T., Gershkovich, P., Stamatopoulos, K., Gowland, P., Stolnik, S., Butler, J., & Marciani, L. (2025). Novel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging. Molecular Pharmaceutics, 22(1), 594-598. https://doi.org/10.1021/acs.molpharmaceut.4c00854

Magnetic resonance imaging (MRI) of dry or solid materials in the gastrointestinal (GI) tract requires the use of contrast agents to enhance visualisation of the dosage forms. In this study, we explore the novel use of manganese gluconate added to ta... Read More about Novel Use of Manganese Gluconate as a Marker for Visualization of Tablet Dissolution in the Fed Human Stomach Using Magnetic Resonance Imaging.

Combined magnetic resonance imaging, high resolution manometry and a randomised trial of bisacodyl versus hyoscine shows the significance of an enlarged colon in constipation: the RECLAIM study (2024)
Journal Article
Wilkinson-Smith, V., Scott, M., Menys, A., Wiklendt, L., MARCIANI, L., Atkinson, D., Sansone, S., Zdanavciene, A., Coupland, C., Knowles, C., Dinning, P., Taylor, S., Gowland, P., Hoad, C., Corsetti, M., & Spiller, R. (2025). Combined magnetic resonance imaging, high resolution manometry and a randomised trial of bisacodyl versus hyoscine shows the significance of an enlarged colon in constipation: the RECLAIM study. Gut, 74(1), 35-44. https://doi.org/10.1136/gutjnl-2024-332755

Background
Colonic motility in constipation can be assessed non-invasively using MRI.

Objective
To compare MRI with high resolution colonic manometry (HRCM) for predicting treatment response.

Design
Part 1: 44 healthy volunteers (HV), 43... Read More about Combined magnetic resonance imaging, high resolution manometry and a randomised trial of bisacodyl versus hyoscine shows the significance of an enlarged colon in constipation: the RECLAIM study.

A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms (2024)
Journal Article
Zareian, N., Eremin, O., Pandha, H., Baird, R., Kwatra, V., Funingana, G., Verma, C., Choy, D., Hargreaves, S., Moghimi, P., Shepherd, A., Lobo, D. N., Eremin, J., Farzaneh, F., Kordasti, S., & Spicer, J. (2024). A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Experimental Biology and Medicine, 249(1), https://doi.org/10.3389/ebm.2024.10021

The presence of inhibitory immune cells and difficulty in generating activated effector T cells remain obstacles to development of effective cancer vaccines. We designed a vaccine regimen combining human telomerase reverse transcriptase (hTERT) pepti... Read More about A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.

Smoking is a risk factor for autoimmune hepatitis: An English registry-based case-control study (2024)
Journal Article
Grønbæk, L., Omeife, H., Ban, L., Crooks, C. J., Card, T. R., Jepsen, P., & West, J. (2024). Smoking is a risk factor for autoimmune hepatitis: An English registry-based case-control study. Clinical Epidemiology, 16, 23-30. https://doi.org/10.2147/CLEP.S439219

Purpose: Smoking is a risk factor for some autoimmune diseases, but its association with autoimmune hepatitis remains unknown. We conducted a population-based matched case–control study to examine the association between tobacco smoking and the risk... Read More about Smoking is a risk factor for autoimmune hepatitis: An English registry-based case-control study.

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. (2023)
Journal Article
Ng, C., Dellschaft, N. S., Hoad, C., Marciani, L., Spiller, R., Crooks, C., Hill, T., Menys, A., Mainz, J. G., Barr, H., Gowland, P. A., Major, G., & Smyth, A. R. (2023). A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes. NIHR Open Research, 3(65), 1-16. https://doi.org/10.3310/nihropenres.13510.1

Background

People with cystic fibrosis (CF) can experience recurrent chest infections, pancreatic exocrine insufficiency and gastrointestinal symptoms. New cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs improve lung fun... Read More about A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes..

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article
Nielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., Irving, W. L., Karsdal, M. A., Patel, K., Leeming, D. J., & Guha, I. N. (2023). PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Reports, 5(6), Article 100743. https://doi.org/10.1016/j.jhepr.2023.100743

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial (2023)
Journal Article
Gunn, D., Topan, R., Barnard, L., Fried, R., Holloway, I., Brindle, R., Corsetti, M., Scott, M., Farmer, A., Kapur, K., Sanders, D., Eugenicos, M., Trudgill, N., Whorwell, P., Mclaughlin, J., Akbar, A., Houghton, L., Dinning, P. G., Aziz, Q., Ford, A. C., …Spiller, R. (2023). Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology and Therapeutics, 57(11), 1258-1271. https://doi.org/10.1111/apt.17426

Summary: Background: Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS‐D). Aim: To conduct a 12‐week parallel group, randomised, double‐blind, placebo‐controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.)... Read More about Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial.

A comparative, randomised MRI study of the physiological and appetitive responses to gelling (alginate) and non-gelling nasogastric tube feeds in healthy men (2023)
Journal Article
Aliyu, A. I., Nixon, A., Hoad, C., Marciani, L., Corsetti, M., Aithal, G. P., Macdonald, I. A., Cordon, S. M., Alhussain, M. H., Inoue, H., Yamada, M., & Taylor, M. A. (2023). A comparative, randomised MRI study of the physiological and appetitive responses to gelling (alginate) and non-gelling nasogastric tube feeds in healthy men. British Journal of Nutrition, 130(8), 1316-1328. https://doi.org/10.1017/S0007114523000302

AbstractInclusion in nasogastric tube feeds (NGTF) of acid-sensitive, seaweed-derived alginate, expected to form a reversible gel in the stomach, may create a more normal intragastric state and modified gastrointestinal responses. This may ameliorate... Read More about A comparative, randomised MRI study of the physiological and appetitive responses to gelling (alginate) and non-gelling nasogastric tube feeds in healthy men.

Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK (2023)
Journal Article
Hamill, V., Gelson, W., MacDonald, D., Richardson, P., Ryder, S. D., Aldersley, M., McPherson, S., Verma, S., Sharma, R., Hutchinson, S., Benselin, J., Barnes, E., Guha, I. N., Irving, W. L., & Innes, H. (2023). Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International, 43(4), 917-927. https://doi.org/10.1111/liv.15528

Background: Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with cured hep... Read More about Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK.

Discovery of a polymer resistant to bacterial biofilm, swarming, and encrustation (2023)
Journal Article
Dubern, J. F., Hook, A. L., Carabelli, A. M., Chang, C. Y., Lewis-Lloyd, C. A., Luckett, J. C., Burroughs, L., Dundas, A. A., Humes, D. J., Irvine, D. J., Alexander, M. R., & Williams, P. (2023). Discovery of a polymer resistant to bacterial biofilm, swarming, and encrustation. Science Advances, 9(4), Article eadd7474. https://doi.org/10.1126/sciadv.add7474

Innovative approaches to prevent catheter-associated urinary tract infections (CAUTIs) are urgently required. Here, we describe the discovery of an acrylate copolymer capable of resisting single- and multispecies bacterial biofilm formation, swarming... Read More about Discovery of a polymer resistant to bacterial biofilm, swarming, and encrustation.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims
The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Patient and Public Involvement and Engagement for PhD Students (2023)
Preprint / Working Paper
Gladman, J. R. F., Stocks, J., Phillips, B., Horobin, A., Wragg, A., Mundey, M., Woodcock, R., Braybrooke, R., Junor, A., Hendy, C., Morgan, K., Prior, M., & Humes, D. Patient and Public Involvement and Engagement for PhD Students

This paper aims to provide useful advice regarding the development of skills for patient and public involvement and engagement (PPIE) in research. The authors of this paper comprise experienced PhD supervisors and trainers, researchers leading PPIE a... Read More about Patient and Public Involvement and Engagement for PhD Students.

The effect of acute and chronic exercise on hepatic lipid composition (2023)
Journal Article
Willis, S. A., Malaikah, S., Parry, S., Bawden, S., Ennequin, G., Sargeant, J. A., Yates, T., Webb, D. R., Davies, M. J., Stensel, D. J., Aithal, G. P., & King, J. A. (2023). The effect of acute and chronic exercise on hepatic lipid composition. Scandinavian Journal of Medicine and Science in Sports, 33(5), 550-568. https://doi.org/10.1111/sms.14310

Exercise is recommended for those with, or at risk of nonalcoholic fatty liver disease (NAFLD), owing to beneficial effects on hepatic steatosis and cardiometabolic risk. Whilst exercise training reduces total intrahepatic lipid in people with NAFLD,... Read More about The effect of acute and chronic exercise on hepatic lipid composition.

Association between prealbumin, all-cause mortality, and response to nutrition treatment in patients at nutrition risk. Secondary analysis of a randomized controlled trial (2023)
Journal Article
Bretscher, C., Buergin, M., Gurzeler, G., Kägi-Braun, N., Gressies, C., Tribolet, P., Lobo, D. N., Evans, D. C., Stanga, Z., Mueller, B., Schuetz, P., & for the EFFORT study team. (2023). Association between prealbumin, all-cause mortality, and response to nutrition treatment in patients at nutrition risk. Secondary analysis of a randomized controlled trial. Journal of Parenteral and Enteral Nutrition, 47(3), 408-419. https://doi.org/10.1002/jpen.2470

Background: Because of the shorter half-life as compared with albumin, serum prealbumin concentrations have been proposed to be useful nutrition biomarkers for the assessment of patients at nutrition risk. In a post hoc analysis of patients at nutrit... Read More about Association between prealbumin, all-cause mortality, and response to nutrition treatment in patients at nutrition risk. Secondary analysis of a randomized controlled trial.

Three Centuries of Appendicectomy (2022)
Journal Article
Herrod, P. J. J., Kwok, A. T., & Lobo, D. N. (2023). Three Centuries of Appendicectomy. World Journal of Surgery, 47(4), 928-936. https://doi.org/10.1007/s00268-022-06874-6

Background
Save for the contribution of Charles McBurney, who described his eponymous point and the appendicectomy incision, the history of appendicectomy is largely unknown among the medical profession. This review traces the history from the first... Read More about Three Centuries of Appendicectomy.

Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction (2022)
Journal Article
Bawden, S. J., Hoad, C., Kaye, P., Stephenson, M., Dolman, G., James, M. W., Wilkes, E., Austin, A., Guha, I. N., Francis, S., Gowland, P., & Aithal, G. P. (2023). Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction. Magnetic Resonance Materials in Physics, Biology and Medicine, 36(4), 553-563. https://doi.org/10.1007/s10334-022-01052-0

Objective: Magnetic resonance spectroscopy (MRS) provides a powerful method of measuring fat fraction. However, previous studies have shown that MRS results give lower values compared with visual estimates from biopsies in fibrotic livers. This study... Read More about Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction.